Atike Pınar Erdoğan1, Ferhat Ekinci2, Aykut Karabaş2, Onur Yazdan Balçık2, Sabri Barutça2, Ahmet Dirican3. 1. Medical Faculty Department Of Internal Medicine Divison Of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey. dr_pinarcan@yahoo.com. 2. Medical Faculty Department Of Internal Medicine Divison Of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey. 3. Department Of Internal Medicine Divison Of Medical Oncology , Izmir Economy University Medical Faculty , İzmir, Turkey.
Abstract
PURPOSE: To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib. METHODS: A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated. RESULTS: According to the cut-off points, patients were divided into two groups. The patients in the high IPI group showed poorer OS compared to patients in the low IPI groups. The PFS was better in patients with low neutrophil-lymphocyte ratio (NLR) and platelet-neutrophil to lymphocyte ratio (PNLR), and the OS was better in patients with low IPI. CONCLUSION: Among the immune inflammation scores analyzed in mCRC patients receiving regorafenib, NLR and PNLR were the best predictor of recurrence, whereas IPI was the best predictor of long-term survival. After being confirmed by better designed controlled trials, IPI can be used to identify the group of patients who will benefit more from regorafenib treatment.
PURPOSE: To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib. METHODS: A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated. RESULTS: According to the cut-off points, patients were divided into two groups. The patients in the high IPI group showed poorer OS compared to patients in the low IPI groups. The PFS was better in patients with low neutrophil-lymphocyte ratio (NLR) and platelet-neutrophil to lymphocyte ratio (PNLR), and the OS was better in patients with low IPI. CONCLUSION: Among the immune inflammation scores analyzed in mCRC patients receiving regorafenib, NLR and PNLR were the best predictor of recurrence, whereas IPI was the best predictor of long-term survival. After being confirmed by better designed controlled trials, IPI can be used to identify the group of patients who will benefit more from regorafenib treatment.
Authors: Nigar Dirican; Ahmet Dirican; Ceyda Anar; Sule Atalay; Onder Ozturk; Ahmet Bircan; Ahmet Akkaya; Munire Cakir Journal: Asian Pac J Cancer Prev Date: 2016-12-01